Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort

REFERENCES

1. 1.↵
   1. Singh JA,
   2. Hodges JS,
   3. Asch SM

   . Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68:1265–70.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Sarawate CA,
   2. Brewer KK,
   3. Yang W,
   4. Patel PA,
   5. Schumacher HR,
   6. Saag KG,
   7. et al.

   Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925–34.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mikuls TR,
   2. Farrar JT,
   3. Bilker WB,
   4. Fernandes S,
   5. Saag KG

   . Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005;44:1038–42.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Sarawate CA,
   2. Patel PA,
   3. Schumacher HR,
   4. Yang W,
   5. Brewer KK,
   6. Bakst AW

   . Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61–5.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Shoji A,
   2. Yamanaka H,
   3. Kamatani N

   . A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321–5.

   OpenUrlCrossRefPubMed
6. 6.
   1. Schumacher HR Jr,
   2. Becker MA,
   3. Lloyd E,
   4. MacDonald PA,
   5. Lademacher C

   . Febuxostat in the treatment of gout: 5-yr findings of the focus efficacy and safety study. Rheumatology 2009;48:188–94.

   OpenUrlCrossRefPubMed
7. 7.
   1. Becker MA,
   2. Schumacher HR,
   3. MacDonald PA,
   4. Lloyd E,
   5. Lademacher C

   . Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273–82.

   OpenUrlAbstract/FREE Full Text
8. 8.
   1. Becker MA,
   2. MacDonald PA,
   3. Hunt BJ,
   4. Lademacher C,
   5. Joseph-Ridge N

   . Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008;27:585–91.

   OpenUrlCrossRefPubMed
9. 9.
   1. Halpern R,
   2. Fuldeore MJ,
   3. Mody RR,
   4. Patel PA,
   5. Mikuls TR

   . The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009;15:3–7.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Sundy JS,
    2. Baraf HS,
    3. Yood RA,
    4. Edwards NL,
    5. Gutierrez-Urena SR,
    6. Treadwell EL,
    7. et al.

    Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711–20.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Khanna D,
    2. Fitzgerald JD,
    3. Khanna PP,
    4. Bae S,
    5. Singh MK,
    6. Neogi T,
    7. et al.

    2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46.

    OpenUrlCrossRefPubMed
12. 12.
    1. Khanna D,
    2. Khanna PP,
    3. Fitzgerald JD,
    4. Singh MK,
    5. Bae S,
    6. Neogi T,
    7. et al.

    2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447–61.

    OpenUrlCrossRef
13. 13.
    1. Zhang W,
    2. Doherty M,
    3. Bardin T,
    4. Pascual E,
    5. Barskova V,
    6. Conaghan P,
    7. et al.

    EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24.

    OpenUrlAbstract/FREE Full Text
14. 14.
    1. Hui M,
    2. Carr A,
    3. Cameron S,
    4. Davenport G,
    5. Doherty M,
    6. Forrester H,
    7. et al.

    The British Society for Rheumatology guideline for the management of gout. Rheumatology 2017;56:e1–e20.

    OpenUrl
15. 15.
    1. Yamanaka H;
    2. Japanese Society of Gout and Nucleic Acid Metabolism

    . Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011;30:1018–29.

    OpenUrlCrossRefPubMed
16. 16.
    1. Sivera F,
    2. Andres M,
    3. Carmona L,
    4. Kydd AS,
    5. Moi J,
    6. Seth R,
    7. et al.

    Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014;73:328–35.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Qaseem A,
    2. Harris RP,
    3. Forciea MA;
    4. Clinical Guidelines Committee of the American College of Physicians

    . Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017;166:58–68.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Pandya BJ,
    2. Riedel AA,
    3. Swindle JP,
    4. Becker LK,
    5. Hariri A,
    6. Dabbous O,
    7. et al.

    Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin 2011;27:737–44.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Halpern R,
    2. Mody RR,
    3. Fuldeore MJ,
    4. Patel PA,
    5. Mikuls TR

    . Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009;25:1711–9.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Rashid N,
    2. Coburn BW,
    3. Wu YL,
    4. Cheetham TC,
    5. Curtis JR,
    6. Saag KG,
    7. et al.

    Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol 2015;42:504–12.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Kiltz U,
    2. Smolen J,
    3. Bardin T,
    4. Cohen Solal A,
    5. Dalbeth N,
    6. Doherty M,
    7. et al.

    Treat-to-target (t2t) recommendations for gout. Ann Rheum Dis 2017;76:632–8.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Richette P,
    2. Doherty M,
    3. Pascual E,
    4. Barskova V,
    5. Becce F,
    6. Castaneda-Sanabria J,
    7. et al.

    2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29–42.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Andersen R,
    2. Newman JF

    . Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973;51:95–124.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Andersen RM

    . Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:1–10.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Boyko EJ,
    2. Koepsell TD,
    3. Gaziano JM,
    4. Horner RD,
    5. Feussner JR

    . US Department of Veterans Affairs medical care system as a resource to epidemiologists. Am J Epidemiol 2000;151:307–14.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Perlin JB,
    2. Kolodner RM,
    3. Roswell RH

    . The Veterans Health Administration: quality, value, accountability, and information as transforming strategies for patient-centered care. Am J Manag Care 2004;10:828–36.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. McGinnis KA,
    2. Fine MJ,
    3. Sharma RK,
    4. Skanderson M,
    5. Wagner JH,
    6. Rodriguez-Barradas MC,
    7. et al.

    Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health 2003;93:1728–33.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Cowper DC,
    2. Hynes DM,
    3. Kubal JD,
    4. Murphy PA

    . Using administrative databases for outcomes research: select examples from VA health services research and development. J Med Syst 1999;23:249–59.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Berlowitz DR,
    2. Halpern J

    . Evaluating and improving pressure ulcer care: The VA experience with administrative data. Jt Comm J Qual Improv 1997;23:424–33.

    OpenUrlPubMed
30. 30.↵
    1. Kashner TM

    . Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. Med Care 1998;36:1324–36.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Szeto HC,
    2. Coleman RK,
    3. Gholami P,
    4. Hoffman BB,
    5. Goldstein MK

    . Accuracy of computerized outpatient diagnoses in a Veterans Affairs general medicine clinic. Am J Manag Care 2002;8:37–43.

    OpenUrlPubMed
32. 32.↵
    1. STROBE statement

    . Checklist of items that should be included in reports of cohort studies. [Internet. Accessed October 30, 2019.] Available from: www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cohort.pdf
33. 33.↵
    1. US Department of Veterans Affairs

    . VA Informatics and Computing Infrastructure (VINCI). Washington, DC; 2011. [Internet. Accessed October 30, 2019.] Available from: www.hsrd.research.va.gov/for_researchers/vinci
34. 34.↵
    1. Charlson ME,
    2. Pompei P,
    3. Ales KL,
    4. MacKenzie CR

    . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Goldberg DS,
    2. French B,
    3. Forde KA,
    4. Groeneveld PW,
    5. Bittermann T,
    6. Backus L,
    7. et al.

    Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans. JAMA 2014;311:1234–43.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. Smith SC,
    2. Shanks C,
    3. Guy G,
    4. Yang X,
    5. Dowell JD

    . Social and demographic factors influencing inferior vena cava filter retrieval at a single institution in the United States. Cardiovasc Intervent Radiol 2015;38:1186–91.

    OpenUrl
37. 37.↵
    1. Singh JA,
    2. Hodges JS,
    3. Toscano JP,
    4. Asch SM

    . Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57:822–9.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Borowsky SJ,
    2. Nelson DB,
    3. Fortney JC,
    4. Hedeen AN,
    5. Bradley JL,
    6. Chapko MK

    . VA community-based outpatient clinics: performance measures based on patient perceptions of care. Med Care 2002;40:578–86.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. VA Midwest Healthcare Network

    . VISN 23. [Internet. Accessed January 20, 2020.] Available from: www.visn23.va.gov
40. 40.↵
    1. Doherty M,
    2. Jenkins W,
    3. Richardson H,
    4. Sarmanova A,
    5. Abhishek A,
    6. Ashton D,
    7. et al.

    Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018;392:1403–12.

    OpenUrl
41. 41.↵
    1. Goldfien R,
    2. Pressman A,
    3. Jacobson A,
    4. Ng M,
    5. Avins A

    . A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Perm J 2016;20:18–23.

    OpenUrl
42. 42.↵
    1. Ramsubeik K,
    2. Ramrattan LA,
    3. Kaeley GS,
    4. Singh JA

    . Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 2018;10:235–52.

    OpenUrl
43. 43.↵
    1. Singh JA,
    2. Edwards NL

    . Patient perceptions of gout management goals: a cross-sectional Internet survey. J Clin Rheumatol 2019 Jan 4 (E-pub ahead of print).
44. 44.↵
    1. Sheer R,
    2. Null KD,
    3. Szymanski KA,
    4. Sudharshan L,
    5. Banovic J,
    6. Pasquale MK

    . Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res 2017;9:629–39.

    OpenUrl
45. 45.↵
    1. Juraschek SP,
    2. Kovell LC,
    3. Miller ER 3rd,
    4. Gelber AC

    . Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res 2015;67:588–92.

    OpenUrl
46. 46.↵
    1. Harrold LR,
    2. Saag KG,
    3. Yood RA,
    4. Mikuls TR,
    5. Andrade SE,
    6. Fouayzi H,
    7. et al.

    Validity of gout diagnoses in administrative data. Arthritis Rheum 2007;57:103–8.

    OpenUrlCrossRefPubMed